FDA Moves to Make GRAS Notification Mandatory

What Happened

On August 11, 2026, the U.S. Food and Drug Administration published a long-anticipated proposed rule that would fundamentally revise the regulatory framework for substances Generally Recognized as Safe (GRAS) in human and animal food. If finalized, the rule would convert FDA's voluntary GRAS notification program — in place since 1997 and formalized in 2016 — into a mandatory notification requirement, ending the practice of purely self-affirmed GRAS status for new substances entering the food supply.

The proposal follows a March 2025 directive from HHS Secretary Robert F. Kennedy Jr. instructing FDA to explore rulemaking that would close the self-affirmation pathway, and builds on other recent Human Foods Program initiatives, including the phase-out of petroleum-based synthetic dyes.

Why It Matters

Under the current system, a company can independently conclude that a substance is GRAS for its intended use and market it — including in food-contact applications — without ever notifying FDA. Voluntary notification has been common, particularly for suppliers who want an FDA "no questions" letter to share with downstream customers, but it has never been required. Over 1,200 substances currently appear in FDA's voluntary GRAS notice inventory; an unknown, and likely larger, number are marketed on the basis of self-affirmed conclusions that were never submitted to FDA at all.

This proposal targets that second category directly. FDA states the goal is to increase transparency and post-market oversight — giving the Agency visibility into substances it currently has no record of, rather than to impose a new safety-approval gate.

What's Actually Changing

1. Mandatory notification

Any company that introduces a substance into interstate commerce based on an independently reached GRAS conclusion would be required to notify FDA and submit the basis for that conclusion — unless a specific exception applies. This covers both substances used directly in food and food-contact ("indirect") substances.

2. A public GRAS notice inventory

FDA would be required to maintain a public-facing inventory of all substances subject to mandatory notification, including their intended conditions of use. Submitters would be responsible for flagging, at the time of filing, any data or information they consider exempt from public disclosure under the Freedom of Information Act — if they don't, FDA will treat it as non-exempt.

3. A streamlined path for substances already on the market

Recognizing how many substances are already marketed under self-determined GRAS conclusions, the rule creates a separate, time-limited streamlined submission option. This requires only basic identifying information about the substance and its conditions of use — not the full underlying safety narrative or data package a standard GRAS notice requires.

4. Still not premarket approval

FDA has been explicit on this point: a GRAS notice is not an application for "GRAS approval." A company may continue marketing a substance both before filing a notice and while it's pending before the Agency — the proposal does not create a waiting period. FDA also states that failing to notify would not, by itself, render a food adulterated; instead, non-notification would be treated as a factor when FDA prioritizes substances for post-market review.

Exceptions to the Mandatory Notice Requirement

The proposed rule would not require a new submission where the intended use is already covered by:

• An existing FDA "no questions" letter
• A substance already listed or affirmed as GRAS by regulation (21 CFR parts 182, 184, or 186)
• An effective Food Contact Notification (FCN) covering the same use
• A Threshold of Regulation (TOR) exemption — which the proposal would also expand to cover substances added directly to food, not just indirect additives
• Another established FDA review process
• A substance already posted to the public list through the streamlined submission pathway

Note that exceptions are use-specific: if the identity, manufacturing process, or conditions of use differ from what was covered in a prior notice or listing, the exception doesn't carry over and a new notice would be required.

Key Dates

What Companies Should Do Now

1. Inventory every ingredient relying on self-determined or self-affirmed GRAS status — including food-contact substances, not just direct additives.
2. Review the scientific basis and supporting documentation behind each GRAS conclusion, and confirm you can locate the original determination package.
3. Map each substance against the proposed exceptions above to identify which ones may already be covered and which will need a new notice or streamlined submission.
4. Distinguish direct food ingredients from food-contact substances — the latter may already be covered by an effective FCN, which changes what's required.
5. Preserve evidence of when each substance entered interstate commerce, which may matter for eligibility under the streamlined pathway.
6. Consider submitting a comment before December 9, 2026, particularly if the proposed exceptions, deadlines, or scope would materially affect your ingredient portfolio.

Frequently Asked Questions

Need Regulatory Support?

Orionex Regulatory Solutions can help assess your GRAS documentation, ingredient compliance, FDA regulatory pathway, and U.S. market-entry strategy — including inventorying self-affirmed substances and identifying which proposed exceptions may apply to your portfolio.

📧 Info@orionexregulatory.com  ·  📱 WhatsApp: +1-307-441-8160

This article discusses a proposed FDA rule and does not represent a final regulatory requirement. The scope, exceptions, and implementation timeline described above may change during the rulemaking process. This content is provided for general informational purposes and does not constitute legal advice.